

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Nai-Kong V. CHEUNG
U.S. Serial No. : 10/565,484
Confirmation No. : 2140
Filed : January 17, 2006
Examiner : Eric Olson
Art Unit : 1623
For : THERAPY-ENHANCING GLUCAN

Law Offices of Albert Wai-Kit Chan, PLLC
World Plaza, Suite 604
141-07 20th Avenue
Whitestone, NY 11357

March 10, 2009

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir/Madam:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

In accordance with his duty of disclosure under 37 C.F.R. §1.56, Applicant would like to direct the Examiner's attention to the following references which are also listed on Forms PTO/SB/08A and PTO/SB/08B (attached hereto as **Exhibit A**). The references are further attached as **Exhibits 1-19**.

1. Chinese Office Action, October 31, 2008, for SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH, Chinese Application No. 200480020356.6 (Atty. Dkt. #639-C-PCT-CN), Filed January 16, 2006, corresponding to PCT/US04/23099. (**Exhibit 1**)

| | | | |
|-----------|----------------------|----------------|------------------|
| Applicant | : Nai-Kong V. CHEUNG | Atty. Dkt. No. | : 639-C-PCT-US |
| USSN | : 10/565,484 | Art Unit | : 1623 |
| Filed | : January 17, 2006 | Date of SIDS | : March 10, 2009 |
| Examiner | : Eric Olson | | |
| Page | : 2 | | |

2. Australian Office Action, December 4, 2008, for SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH and BIOTEC PHARMACON ASA, Australian Application No. 2008207369 (Atty. Dkt. #639-G-PCT-AU), Filed August 18, 2008, corresponding to PCT/US2007/001427. **(Exhibit 2)**
3. Indian First Examination Report, February 12, 2009, for SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH, Indian Application No. 186/MUMNP/2006 (Atty. Dkt. #639-C-PCT-IN), Filed February 15, 2006, corresponding to PCT/US04/23099. **(Exhibit 3)**
4. ALLENDORF et al., 2005, "C5a-Mediated Leukotriene B₄-Amplified Neutrophil Chemotaxis Is Essential in Tumor Immunotherapy Facilitated by Anti-Tumor Monoclonal Antibody and β -Glucan", Journal of Immunology, 174:7050-7056. **(Exhibit 4)**
5. CHAN et al., 2007, "Response of human dendritic cells to different immunomodulatory polysaccharides derived from mushroom and barley", International Immunology, 19(7):891-899. **(Exhibit 5)**
6. CHEUNG et al., 1994, "Antibody Response to Murine Anti-G_{D2} Monoclonal Antibodies:Correlation with Patient Survival", Cancer Research, 54(8):2228-2233. **(Exhibit 6)**
7. CHEUNG et al., 2006, "FCGR2A Polymorphism Is Correlated With Clinical Outcome After Immunotherapy of Neuroblastoma With Anti-GD2 Antibody and Granulocyte Macrophage Colony-Stimulating Factor", Journal Clinical Oncology, 24(18):2885-2890. **(Exhibit 7)**

| | | | |
|-----------|----------------------|----------------|------------------|
| Applicant | : Nai-Kong V. CHEUNG | Atty. Dkt. No. | : 639-C-PCT-US |
| USSN | : 10/565,484 | Art Unit | : 1623 |
| Filed | : January 17, 2006 | Date of SIDS | : March 10, 2009 |
| Examiner | : Eric Olson | | |
| Page | : 3 | | |

8. DHODAPKAR et al., 2002, "Antitumor Monoclonal Antibodies Enhance Cross-Presentation of Cellular Antigens and the Generation of Myeloma-specific Killer T Cells by Dendritic Cells", Journal Experimental Medicine, 195(1):125-133. **(Exhibit 8)**
9. DIAZ DE STAHL et al., 2003, "A role for complement in feedback enhancement of antibody responses by IgG3", Journal Experimental Medicine, 197(9):1183-1190. **(Exhibit 9)**
10. DILLMAN et al., 2001, "Monoclonal antibodies in the treatment of malignancy: Basic concepts and recent developments", Cancer Investigation, 19(8):833-841. **(Exhibit 10)**
11. GELDERMAN et al., 2004, "Complement function in mAb-mediated cancer immunotherapy", TRENDS in Immunology, 25(3):158-164. **(Exhibit 11)**
12. HONG et al., 2003, " β -Glucan Functions as an Adjuvant for Monoclonal Antibody Immunotherapy by Recruiting Tumoricidal Granulocytes as Killer Cells", Cancer Research, 63(24):9023-9031. **(Exhibit 12)**
13. IANNELLO et al., 2005, "Role of antibody-dependent cell-mediated cytotoxicity in the efficacy of therapeutic anti-cancer monoclonal antibodies", Cancer Metastasis, 24(4):487-499. **(Exhibit 13)**
14. IMAI et al., 2005, "Complement-Mediated Mechanisms in Anti-GD2 Monoclonal Antibody Therapy of Murine Metastatic Cancer", Cancer Research, 65(22):10562-10568. **(Exhibit 14)**

| | | | |
|-----------|----------------------|----------------|------------------|
| Applicant | : Nai-Kong V. CHEUNG | Atty. Dkt. No. | : 639-C-PCT-US |
| USSN | : 10/565,484 | Art Unit | : 1623 |
| Filed | : January 17, 2006 | Date of STDS | : March 10, 2009 |
| Examiner | : Eric Olson | | |
| Page | : 4 | | |

15. KUSHNER et al., 2001, "Phase II Trial of the Anti-G_{D2} Monoclonal Antibody 3F8 and Granulocyte-Macrophage Colony-Stimulating Factor for Neuroblastoma", Journal Clinical Oncology, 19(22):4189-94. **(Exhibit 15)**

16. LI et al., 2007, "Combined Yeast β -Glucan and Antitumor Monoclonal Antibody Therapy Requires C5a-Mediated Neutrophil Chemotaxis via Regulation of Decay-Accelerating Factor CD55", Cancer Research, 67:7421-7430. **(Exhibit 16)**

17. YAN et al., 2005, "Yeast whole glucan particle β -glucan in conjunction with antitumor monoclonal antibodies to treat cancer", Expert Opinion on Biological Therapy, 5(5):691-702. **(Exhibit 17)**

18. YOSHITOMI et al., 2005, "A role for fungal β -glucans and their Dectin-1 in the induction of autoimmune arthritis in genetically susceptible mice", Journal of Experimental Medicine, 201(6):949-960. **(Exhibit 18)**

19. ZHANG et al., 1998, "Antibodies against GD2 Ganglioside Can Eradicate Syngeneic Cancer Micrometastases", Cancer Research, 58(13):2844-2849. **(Exhibit 19)**

| | | | |
|-----------|----------------------|----------------|------------------|
| Applicant | : Nai-Kong V. CHEUNG | Atty. Dkt. No. | : 639-C-PCT-US |
| USSN | : 10/565,484 | Art Unit | : 1623 |
| Filed | : January 17, 2006 | Date of SIDS | : March 10, 2009 |
| Examiner | : Eric Olson | | |
| Page | : 5 | | |

If a telephone interview would be of assistance in advancing prosecution of this application, Applicant's undersigned attorney invites the Examiner to telephone him at the number provided below. No fee is deemed necessary in connection with the filing of this SIDS. However, if any fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 50-1891.

Respectfully submitted,

Albert Wai Kit Chan

Albert Wai-Kit Chan
Registration No. 36,479
Attorney for Applicant
Law Offices of
Albert Wai-Kit Chan, PLLC
World Plaza, Suite 604
141-07 20th Avenue
Whitestone, New York 11357
Tel: (718) 799-1000
Fax: (718) 357-8615
e-mail: chank@kitchenlaw.com